Fregonese, FedericaAhuja, Shama DAkkerman, Onno WArakaki-Sanchez, DeniseAyakaka, IreneBaghaei, ParvanehBang, DidiBastos, MayaraBenedetti, AndreaBonnet, MarylineCattamanchi, AdithyaCegielski, PeterChien, Jung-YienCox, HelenDedicoat, MartinErkens, ConnieEscalante, PatricioFalzon, DennisGarcia-Prats, Anthony JGegia, MedeaGillespie, Stephen HGlynn, Judith RGoldberg, StefanGriffith, DavidJacobson, Karen RJohnston, James CJones-López, Edward CKhan, AwalKoh, Won-JungKritski, AfranioLan, Zhi YiLee, Jae HoLi, Pei ZhiMaciel, Ethel LGalliez, Rafael MelloMerle, Corinne S CMunang, MelindaNarendran, GopalanNguyen, Viet NhungNunn, AndrewOhkado, AkihiroPark, Jong SunPhillips, Patrick P JPonnuraja, ChinnaiyanReves, RandallRomanowski, KamilaSeung, KwonjuneSchaaf, H SimonSkrahina, AlenaSoolingen, Dick vanTabarsi, PayamTrajman, AneteTrieu, LisaBanurekha, Velayutham VViiklepp, PiretWang, Jann-YuanYoshiyama, TakashiMenzies, Dick2018-04-192018-04-192018-04Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. 2018, 6 (4):265-275 Lancet Respir Med2213-26192959550910.1016/S2213-2600(18)30078-Xhttp://hdl.handle.net/10029/621805Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure, relapse, and acquired rifampicin resistance if treated with first-line anti-tuberculosis drugs. The aim of the study was to compare success, mortality, and acquired rifampicin resistance in patients with INH-R pulmonary tuberculosis given different durations of rifampicin, ethambutol, and pyrazinamide (REZ); a fluoroquinolone plus 6 months or more of REZ; and streptomycin plus a core regimen of REZ.enArchived with thanks to The Lancet. Respiratory medicineArticleLancet Respir Med 2018; 6(4):265-75